Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Equity Ratio (2016 - 2026)

Lexaria Bioscience's Equity Ratio history spans 12 years, with the latest figure at 0.96 for Q1 2026.

  • Quarterly results put Equity Ratio at 0.96 for Q1 2026, up 22.87% from a year ago — trailing twelve months through Feb 2026 was 0.96 (up 22.87% YoY), and the annual figure for FY2025 was 0.62, down 27.82%.
  • Equity Ratio for Q1 2026 was 0.96 at Lexaria Bioscience, up from 0.75 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 96.71 in Q1 2024 to a low of 0.62 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.97 (2022), against an average of 18.7.
  • The sharpest move saw Equity Ratio surged 7923.19% in 2022, then plummeted 99.19% in 2025.
  • Year by year, Equity Ratio stood at 78.34 in 2022, then crashed by 43.53% to 44.24 in 2023, then plummeted by 97.83% to 0.96 in 2024, then decreased by 22.06% to 0.75 in 2025, then increased by 28.05% to 0.96 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.96, 0.75, and 0.62 for Q1 2026, Q4 2025, and Q3 2025 respectively.